Auctus Therapeutics

Auctus Therapeutics is a biotechnology company focused on the development of next-generation targeted therapies for cancer, specifically leveraging its proprietary P9 technology platform. The company specializes in creating high-potency antibody-drug conjugates (ADCs) and radiopharmaceuticals designed to deliver therapeutic payloads with high precision to tumor cells while minimizing off-target effects. Founded and incubated by Deerfield Management in collaboration with Johns Hopkins University, Auctus aims to address unmet needs in oncology through innovative engineering of antibody-based delivery systems. The company is headquartered in the Cure building in New York City, benefiting from a robust life sciences ecosystem and a leadership team with deep expertise in drug discovery and commercialization.